We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Scopus Biopharma Inc (SCPS) USD0.001

Sell:$0.0011 Buy:$0.0011 Change: No change
Market closed |  Prices as at close on 9 May 2024 | Switch to live prices |
Sell:$0.0011
Buy:$0.0011
Change: No change
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Deal now
Market closed |  Prices as at close on 9 May 2024 | Switch to live prices |
Sell:$0.0011
Buy:$0.0011
Change: No change
Market closed |  Prices as at close on 9 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.

Contact details

Address:
420 Lexington Ave Rm 300
NEW YORK
10170-0399
United States
Telephone:
+1 (212) 4792513
Website:
https://scopusbiopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SCPS
ISIN:
US8091711015
Market cap:
$88,380
Shares in issue:
42.08 million
Sector:
Biotechnology
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Joshua Lamstein
    Chairman of the Board, Principal Executive Officer
  • Robert Gibson
    Vice Chairman of the Board, Treasurer, Secretary
  • Alan Horsager
    President - Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics
  • Aharon Schwartz
    Executive Chairman of Scopus BioPharma Israel Ltd

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.